BDTX
Black Diamond Therapeutics, Inc. NASDAQ Listed Jan 31, 2020$2.73
Mkt Cap $156.4M
52w Low $1.53
35.2% of range
52w High $4.94
50d MA $2.49
200d MA $2.94
P/E (TTM)
6.7x
EV/EBITDA
6.5x
P/B
1.3x
Debt/Equity
0.1x
ROE
19.9%
P/FCF
4.7x
RSI (14)
—
ATR (14)
—
Beta
3.39
50d MA
$2.49
200d MA
$2.94
Avg Volume
712.1K
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
One Main Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.18 | -0.14 | +22.2% | 2.19 | -3.7% | +1.8% | -2.7% | -0.9% | -1.9% | +1.9% | — |
| Nov 6, 2025 | AMC | -0.22 | -0.15 | +31.8% | 3.98 | -1.3% | -2.3% | +12.1% | +6.0% | +5.4% | -7.8% | — |
| Aug 7, 2025 | AMC | -0.25 | -0.19 | +24.0% | 2.28 | +0.0% | +5.3% | -3.8% | +10.0% | +9.1% | +0.7% | — |
| May 12, 2025 | AMC | 0.02 | 0.98 | +4800.0% | 1.75 | +10.9% | +10.3% | -2.1% | +2.1% | +1.0% | +8.2% | — |
| Mar 6, 2025 | AMC | -0.31 | -0.28 | +9.7% | 1.90 | -3.2% | -1.1% | -9.0% | -1.2% | +5.9% | -7.8% | — |
| Nov 5, 2024 | AMC | -0.37 | -0.28 | +24.3% | 3.25 | +0.9% | +1.2% | -3.3% | +3.5% | +2.7% | -4.1% | — |
| Aug 6, 2024 | AMC | -0.39 | -0.36 | +7.7% | 5.01 | -0.2% | -9.0% | +6.4% | -4.3% | +0.9% | +14.5% | — |
| May 9, 2024 | AMC | -0.44 | -0.35 | +20.5% | 6.75 | -2.2% | -9.5% | -2.8% | -3.4% | -5.2% | -3.7% | — |
| Mar 12, 2024 | AMC | -0.47 | -0.34 | +27.7% | 3.78 | +1.3% | +10.8% | +8.4% | +5.5% | -1.9% | -1.5% | — |
| Nov 6, 2023 | AMC | -0.49 | -0.45 | +8.2% | 1.91 | +0.0% | -4.7% | +1.6% | -2.7% | -1.1% | +6.7% | — |
| Aug 11, 2023 | AMC | -0.54 | -0.52 | +3.7% | 3.33 | +2.7% | -1.2% | -3.6% | -2.8% | +0.0% | +2.6% | — |
| May 9, 2023 | AMC | -0.61 | -0.57 | +6.6% | 1.82 | +0.5% | +3.3% | +2.1% | -1.6% | +2.1% | -5.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | BTIG | Maintains | Buy → Buy | — | $2.70 | $2.74 | +1.5% | -4.8% | +3.1% | -1.9% | +3.8% | +6.3% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $2.19 | $2.11 | -3.7% | +1.8% | -2.7% | -0.9% | -1.9% | +1.9% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.67 | $2.66 | -0.4% | -4.1% | -6.2% | +7.1% | +3.1% | -1.5% |
| Dec 4 | Guggenheim | Downgrade | Buy → Neutral | — | $2.69 | $2.70 | +0.4% | +0.7% | -1.5% | +3.0% | -1.5% | -1.5% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $2.43 | +1.2% | -3.8% | +10.0% | +9.1% | +0.7% | -1.1% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.73 | +1.2% | -1.8% | +2.4% | +9.3% | -5.3% | -5.6% |
| Mar 7 | Stifel | Maintains | Buy → Buy | — | $1.90 | $1.84 | -3.2% | -1.1% | -9.0% | -1.2% | +5.9% | -7.8% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.25 | $3.28 | +0.9% | +1.2% | -3.3% | +3.5% | +2.7% | -4.1% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.56 | $3.54 | -0.6% | -0.3% | -3.1% | -3.2% | +4.5% | -2.3% |
| Oct 8 | Wedbush | Maintains | Outperform → Outperform | — | $3.66 | $3.61 | -1.4% | -2.7% | -0.3% | -3.1% | -3.2% | +4.5% |
| Sep 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.50 | +0.0% | +1.8% | -8.3% | +5.0% | -4.1% | +2.8% |
| Sep 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.76 | $5.64 | +18.5% | -5.5% | +1.8% | -8.3% | +5.0% | -4.1% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.83 | $4.88 | +1.0% | -2.1% | +1.1% | -0.4% | -5.5% | +1.8% |
| Sep 10 | Wedbush | Maintains | Outperform → Outperform | — | $5.66 | $5.66 | +0.0% | +7.1% | +1.2% | -4.6% | +5.8% | -12.4% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.77 | $5.70 | -1.2% | -2.6% | -0.7% | -3.2% | +4.8% | +7.1% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $5.01 | $5.00 | -0.2% | -9.0% | +6.4% | -4.3% | +0.9% | +14.5% |
| Jul 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.21 | $4.23 | +0.5% | +5.5% | +0.7% | -2.2% | +14.6% | +2.4% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.61 | -0.9% | +11.6% | -1.5% | +19.4% | +2.3% | -1.1% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.44 | +0.0% | -3.7% | -7.1% | +0.6% | +1.4% | +1.4% |
| Apr 8 | Wedbush | Maintains | Outperform → Outperform | — | $5.06 | $5.24 | +3.6% | +5.7% | +0.2% | -7.1% | +11.8% | -5.9% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.79 | $4.92 | +2.7% | -1.9% | -1.5% | +0.4% | +16.3% | +6.1% |
| Mar 13 | Wedbush | Maintains | Outperform → Outperform | — | $3.78 | $3.83 | +1.3% | +10.8% | +8.4% | +5.5% | -1.9% | -1.5% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.23 | $2.25 | +0.9% | +4.9% | -3.4% | -0.9% | -0.4% | -2.7% |
| Sep 12 | Wedbush | Maintains | Outperform → Outperform | — | $3.48 | $3.47 | -0.3% | +2.0% | +0.8% | +0.6% | -1.4% | -1.4% |
| Jun 30 | Stifel | Upgrade | Hold → Buy | — | $5.03 | $5.32 | +5.8% | +0.4% | -7.1% | +3.6% | -7.8% | -1.6% |
| Jun 28 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $6.18 | $5.85 | -5.3% | -7.3% | -12.2% | +0.4% | -7.1% | +3.6% |
| Jun 27 | Stifel | Maintains | Hold → Hold | — | $1.84 | $4.17 | +126.6% | +235.9% | -7.3% | -12.2% | +0.4% | -7.1% |
| Jun 27 | Wedbush | Upgrade | Neutral → Outperform | — | $1.84 | $4.17 | +126.6% | +235.9% | -7.3% | -12.2% | +0.4% | -7.1% |
| May 10 | Wedbush | Maintains | Neutral → Neutral | — | $1.82 | $1.83 | +0.5% | +3.3% | +2.1% | -1.6% | +2.1% | -5.7% |
| Mar 29 | Wedbush | Downgrade | Outperform → Neutral | — | $2.76 | $2.75 | -0.4% | +1.8% | -1.4% | +0.0% | -0.7% | +1.1% |
| Mar 22 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.11 | $3.00 | -3.5% | +1.6% | -0.3% | -1.3% | -10.3% | -1.1% |
| Mar 18 | Stifel | Maintains | Hold → Hold | — | $3.02 | $3.07 | +1.7% | +5.0% | -1.9% | +1.6% | -0.3% | -1.3% |
| Sep 30 | Stifel | Maintains | Hold → Hold | — | $9.06 | $9.05 | -0.1% | -6.6% | +0.2% | -5.0% | -2.1% | -2.5% |
| Jan 7 | Wedbush | Maintains | Outperform → Outperform | — | $33.23 | $34.08 | +2.6% | +2.3% | +0.3% | +1.9% | -14.8% | +0.5% |
| Nov 24 | Berenberg | Maintains | Buy → Buy | — | $33.54 | $34.92 | +4.1% | +1.3% | -1.6% | +2.9% | -3.1% | -3.3% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.49 | $33.79 | -2.0% | +7.9% | +1.8% | +1.5% | +4.5% | +5.0% |
| Feb 24 | JP Morgan | Maintains | Overweight → Overweight | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
| Feb 24 | Jefferies | Maintains | Buy → Buy | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
| Feb 24 | Cowen & Co. | Maintains | Outperform → Outperform | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
| Feb 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
No insider trades available.
Data updated apr 24, 2026 9:03pm
· Source: massive.com